Emerging preclinical and clinical profile of 311c90: A poster review and discussion

European Neurology

Volumn 36, Issue , 1996, Pages 19-23

  Ferrari, Michel D ^a  

^a NONE

Author keywords

311C90; Antiemetic effects; Clinical pharmacology; Efficacy; Quality of life; Receptor specificity; Safety; Trigemino vascular system; Vasoconstriction

Indexed keywords

SEROTONIN AGONIST; SEROTONIN RECEPTOR; ZOLMITRIPTAN;

ANTIEMETIC ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; HUMAN; MIGRAINE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QUALITY OF LIFE; TRIGEMINAL NUCLEUS; VASOCONSTRICTION;

ANIMALS; CENTRAL NERVOUS SYSTEM; CLINICAL TRIALS; DRUG EVALUATION, PRECLINICAL; HUMANS; MIGRAINE DISORDERS; OXAZOLES; OXAZOLIDINONES; QUALITY OF LIFE; SEROTONIN AGONISTS; TRYPTAMINES;

EID: 0030022963     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000119099     Document Type: Article

References (23)

1. u agonists for the acute treatment of migraine. Headache 1994; 34:307.
2. Hill AP, Hyde RM, Robertson AD, Woollard PM, Glen RC, Martin GR: Oral delivery of 5-HT, receptor agonists: towards the discovery of 3IIC90. a novel anti-migraine agent. Headache 1994:34:308.
3. Martin GR, MacLennan SJ, Cambridge D, Whiting MV: Effect of 311C90 on regional blood flows and systemic haemodynamics in anaesthetised dogs and cats. Headache 1994: 34:311.
4. Martin GR, Robertson AD, MacLennan SJ, Prentice DJ, Honey A, Barrett VJ: 31IC90: a novel, selective 5-HT, receptor partial agonist for the acute treatment of migraine. Headache 1994:34:299.
5. Goadsby PJ, Edvinsson L: Peripheral and central trigémino-vascular activation in cat is blocked by the serotonin (5-HT1-ID receptor agonist 311C90. Headache 1994:34:394-399.
6. Goadsby PJ, Hoskin KL: Trigeminal neuronal activity is inhibited by intravenous administration of 311C90 in the cat. Cephalalgia 1995: 15(suppl 14): 106.
7. Mills A, Rhodes P, Martin GR: [H]31IC90 binding sites in cat brain stem: implications for migraine treatment. Cephalalgia 1995: 15 (suppl 14): 116.
8. Mills A, Martin GR: Labelling of cat brainstem sections with ['H]31 lC90and the 5-HT, receptor ligand [H]BRL43694. Cephalalgia 1995: 15(suppl 14):213.
9. Knight YE, Goadsby PJ: Central nervous system distribution of [H]3I IC90 in cat. Cephalalgia 1995:15(suppl 14):214.
10. Seaber E, On N, Dixon R, Phillips S, Posner J, Rolan P: The pharmacokinetics of and tolera-bility to the novel antimigraine compound 31IC90 in healthy male volunteers. Headache 1995:35:304.
11. Dixon R, On N, Seaber E, Rolan P, Posner J: Lack of an interaction between 3IIC90. a novel antimigraine compound, and oral ergota-minc in healthy subjects. Headache 1995: 35:304.
12. Seaber E, On N, Dixon R, Posner J: The metabolic disposition of the novel antimigraine compound 3I1C90. Cephalalgia 1995; 15 (suppl 14):215.
13. Seaber E, On N, Jackson S, Dixon R, Watt H, Posner J: Similar pharmacokinetics and tolera-bility of the novel antimigrainc compound 3I1C90 in young and elderly volunteers. Cephalalgia 1995; 15(suppl 14):216.
14. 1D agonist, 311C90. Cephalalgia 1995; 15(suppl 14):218.
15. Smith DA, Phillips L, Fleck RJ, Lasseter KC, Shamblem S, Adam KD: 31IC90 in normoten-sive and mild to moderate hypertensive volunteers: a pharmacodynamic and pharmacokinetic comparison. Cephalalgia 1995:15 (suppl 14):219.
16. Mercer AJ, Lamb RJ, Posner J: The effects of 311C90. a novel 5HT, agonist for the treatment of migraine, lorazcpam and placebo on psychometric task performance in healthy volunteers. Headache 1995:35:304.
17. Ferrari MD: The clinical effectiveness of 311C90 in the acute treatment of migraine. Eur Neurol 1996:36(suppl 2):47.
18. Earl NL: Clinical safety of 311C90: Aggregated data from patients and volunteers to date. Eur Neurol 1996:36(suppl 2):8 -12.
19. Giorgi L, Dixon R, Touw K: Cardiovascular safety of the novel antimigraine compound 311C90. Cephalalgia 1995; 15(suppl 14):220.
20. Rapoport AM, Cady RK, Mathew NT, Ramadan NM, Taylor FR, Saper JR, Earl NL, Brown DL: for the US 311C90 Dose Ranging Study Group: Optimizing the oral dose of 311C90 in the acute treatment of migraine. Cephalalgia 1995; 15(suppl 14):22l.
21. Lowy MT, Kench S, Miles P: for The International 311C90 Long-Term Study Group: Eval-ualion of the long-term safety and efficacy of 311C90 in the treatment of migraine. Cephalalgia 1995; 15(suppl 14):222.
22. Sweet R, Klein KB: 31IC90 is effective in good, fair and poor responders to existing therapies for acute migraine. Cephalalgia 1995: 15(suppl 14):223.
23. McKenna S, Patrick D: Development of a migraine specific quality of life measure for multinational clinical trials. Cephalalgia 1995; 15(suppl 14):280.